Allegations of off-label marketing have been suggested in the case of both Fentora and Actiq. Allegedly Fentora and Actiq were marketed as acceptable drugs ...
The increase in sales is partly attributed to Pliva's product line and a generic version of Actiq launched in 2006. Meanwhile, sales of the company's ...
Sales of the company's pain drug, which includes Actiq, plunged 33 percent to $121.8 million on generic competition. Sales of central nervous system drugs ...
Sales of the company's pain medications, including Actiq, which is facing generic competition, sank 33 percent. Actiq sales were $56 million, compared with ...
Adjusted net income declined 30% because of increasing competition from Barr Pharmaceuticals (NYSE: BRL) and its generic version of Cephalon's ACTIQ ...
Sales of the company's pain medications, including Actiq, which is facing generic competition, sank 33 percent. Actiq sales were $56 million, compared with ...
The company's generic product sales doubled to $434 mil on its Pliva product, a knockoff of Actiq. It sees Q4 EPS of 73-83 cents vs. views of 83 cents. ...
Sales of the company's pain drug, which includes Actiq, plunged 33 percent to $121.8 million on generic competition. Sales of central nervous system drugs ...
Adjusted net income declined 30% because of increasing competition from Barr Pharmaceuticals (NYSE: BRL) and its generic version of Cephalon's ACTIQ ...
The increase also reflects strong sales of Fentanyl Citrate, a generic version of ACTIQ(R) that we launched in late September 2006. ...